Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-48574 in adults with T2-low/non-T2 severe uncontrolled asthma
2020-001927-15Phase 2Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma and Severe uncontrolled asthma (SUA) comparing TEV-48574 with Placebo (2 arms). Primary endpoint: Proportion of patients with loss of asthma control during treatment. Started Sep 2020; status: completed.
02
Drugs
duvakitug
03
Conditions
asthmaSevere uncontrolled asthma (SUA)
Beyond the preview
Go deeper on 2020-001927-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001927-15.